Semaglutide Weight Loss: The Trial Evidence

The short version

If you came for the semaglutide weight loss numbers, here they are in plain terms. In the biggest trial of adults with overweight or obesity and no diabetes, average weight dropped about 14.9% over roughly 16 months — that is around 33 pounds for a 220-pound person — against about 2.4% on a dummy injection ^[1]. The loss holds with continued use: a two-year study showed it stayed well ahead of placebo ^[8]. But it is not a one-and-done. When people stop, weight comes back — about 11.6 percentage points of it within a year in one study ^[17]. It works mainly by quieting appetite from the brain, not by speeding up metabolism ^[4]. A newer drug, tirzepatide, beat it on weight in a direct comparison ^[7]. The details, and the honest caveats, follow.

How much weight, and how fast

The anchor number is from STEP 1: 1,961 adults with overweight or obesity and no diabetes, once-weekly 2.4 mg semaglutide or placebo for 68 weeks, mean body-weight change -14.9% versus -2.4% — a gap of about 12.4 percentage points ^[1]. That is a magnitude of pharmacological weight loss the field had not seen outside surgery.

The pace is gradual by design. The dose is stepped up over the first four months, and weight comes off steadily over the full trial rather than in an early crash. People in user reports describe the same arc — noticeable early appetite suppression, then steady loss that slows after the first stretch — which lines up with how the trials measured it.

Durability — and the rebound

Sustained use sustains the loss. STEP 5 followed adults for two years and found weight reduction was maintained and significantly greater than placebo across 104 weeks ^[8]. STEP 4's withdrawal design made the dependence explicit: staying on the drug after a 20-week run-in produced a further -7.9%, while switching to placebo produced +6.9% regain ^[9].

The rebound after stopping entirely is the part worth being clear-eyed about. The STEP 1 extension found a mean regain of roughly 11.6 percentage points of body weight within a year of discontinuation, with cardiometabolic improvements drifting back toward baseline ^[17]. The research framing is consistent: this behaves like a chronic treatment for a chronic condition, not a temporary fix.

Why it works — and what gets lost with the fat

The weight loss is appetite-driven, not metabolism-driven. Rodent studies showed semaglutide reaches the brain's appetite circuits — the arcuate nucleus and brainstem — to cut food intake and shift food preference without lowering energy expenditure ^[4]. In people, that shows up as smaller portions and quieter cravings.

One caveat the body-composition data raises: a DXA substudy found the weight lost included both fat and a meaningful proportion of lean (muscle) mass ^[16]. Fast, large weight loss can erode muscle, which is why the literature flags a sarcopenia concern — especially in older adults — and points toward adequate protein and resistance training as active research areas. It is also the most likely reason behind reports of hair shedding and a gaunter face: rapid weight loss, not a direct drug effect ^[19].

Adolescents, and the tirzepatide comparison

The weight-loss evidence is not adults-only. In STEP TEENS, adolescents with obesity had a significantly greater BMI reduction on once-weekly 2.4 mg than on placebo over 68 weeks ^[10].

And the comparison everyone asks about: in SURMOUNT-5, a direct head-to-head in 751 adults with obesity, tirzepatide produced greater mean weight loss than semaglutide at 72 weeks — -20.2% versus -13.7% (P<0.001) ^[7]. Tirzepatide hits two receptors to semaglutide's one, and on this endpoint it won. Semaglutide still holds the deeper cardiovascular- and kidney-outcomes record ^[3][6], so the better choice depends on which outcome matters most — a point covered on the Semaglutide research page.